Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales
- PMID: 25797312
- DOI: 10.1016/j.atherosclerosis.2015.03.003
Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales
Abstract
Background/objective: Familial Hypercholesterolaemia (FH) is caused by mutations in genes of the Low Density Lipoprotein (LDL) receptor pathway. A definitive diagnosis of FH can be made by the demonstration of a pathogenic mutation. The Wales FH service has developed scoring criteria to guide selection of patients for DNA testing, for those referred to clinics with hypercholesterolaemia. The criteria are based on a modification of the Dutch Lipid Clinic scoring criteria and utilise a combination of lipid values, physical signs, personal and family history of premature cardiovascular disease. They are intended to provide clinical guidance and enable resources to be targeted in a cost effective manner.
Methods: 623 patients who presented to lipid clinics across Wales had DNA testing following application of these criteria.
Results: The proportion of patients with a pathogenic mutation ranged from 4% in those scoring 5 or less up to 85% in those scoring 15 or more. LDL-cholesterol was the strongest discriminatory factor. Scores gained from physical signs, family history, coronary heart disease, and triglycerides also showed a gradient in mutation pick-up rate according to the score.
Conclusion: These criteria provide a useful tool to guide selection of patients for DNA testing when applied by health professionals who have clinical experience of FH.
Keywords: Cholesterol; Criteria; Diagnosis; Familial Hypercholesterolaemia; Genetics.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Genetic analysis of familial hypercholesterolaemia in Western Australia.Atherosclerosis. 2012 Oct;224(2):430-4. doi: 10.1016/j.atherosclerosis.2012.07.030. Epub 2012 Jul 27. Atherosclerosis. 2012. PMID: 22883975
-
Diagnosis and treatment of familial hypercholesterolaemia.Eur Heart J. 2013 Apr;34(13):962-71. doi: 10.1093/eurheartj/eht015. Epub 2013 Feb 14. Eur Heart J. 2013. PMID: 23416791 Review.
-
Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.Eur J Prev Cardiol. 2017 Jul;24(10):1051-1059. doi: 10.1177/2047487317702040. Epub 2017 Mar 29. Eur J Prev Cardiol. 2017. PMID: 28353356
-
Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.Atherosclerosis. 2018 Oct;277:392-398. doi: 10.1016/j.atherosclerosis.2018.06.013. Atherosclerosis. 2018. PMID: 30270076
-
Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.Clin Sci (Lond). 2015 Jul;129(1):63-79. doi: 10.1042/CS20140755. Clin Sci (Lond). 2015. PMID: 25881720 Review.
Cited by
-
Developing a Hybrid Risk Assessment Tool for Familial Hypercholesterolemia: A Machine Learning Study of Chinese Arteriosclerotic Cardiovascular Disease Patients.Front Cardiovasc Med. 2022 Aug 3;9:893986. doi: 10.3389/fcvm.2022.893986. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35990942 Free PMC article.
-
Clinical Evaluation of Patients with Genetically Confirmed Familial Hypercholesterolemia.J Clin Med. 2023 Jan 29;12(3):1030. doi: 10.3390/jcm12031030. J Clin Med. 2023. PMID: 36769678 Free PMC article.
-
PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks.Am J Cardiovasc Drugs. 2021 Jan;21(1):83-92. doi: 10.1007/s40256-020-00411-3. Am J Cardiovasc Drugs. 2021. PMID: 32514867 Free PMC article.
-
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.Eur J Prev Cardiol. 2017 Sep;24(13):1383-1401. doi: 10.1177/2047487317717346. Epub 2017 Jun 23. Eur J Prev Cardiol. 2017. PMID: 28644091 Free PMC article. Review.
-
Improving the yield of genetic testing in familial hypercholesterolaemia.Eur Heart J. 2017 Feb 21;38(8):574-576. doi: 10.1093/eurheartj/ehw166. Eur Heart J. 2017. PMID: 27161618 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous